CA2239520C - Use of 1-hydroxy-2-pyridones for treating mucosal disorders which are difficult to treat - Google Patents
Use of 1-hydroxy-2-pyridones for treating mucosal disorders which are difficult to treat Download PDFInfo
- Publication number
- CA2239520C CA2239520C CA002239520A CA2239520A CA2239520C CA 2239520 C CA2239520 C CA 2239520C CA 002239520 A CA002239520 A CA 002239520A CA 2239520 A CA2239520 A CA 2239520A CA 2239520 C CA2239520 C CA 2239520C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- hydroxy
- methyl
- employed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The use of 1-hydroxy-2-pyridones for the treatment of mucosal disorders which are difficult to treat The compound of the formula I (see formula I) is suitable for the preparation of pharmaceuticals for the treatment of fungal disorders caused by azole-resistant fungi.
Description
f- WO 97/20560 - 1 - PCTIEP96/05132 Description The use of 1-hydroxy-2-pyridones for the treatment of mucosal disorders which are difficult to treat The number of mucosal disorders which are difficult to treat has considerably increased in recent times, and the increasing trend continues.
The mucosal disorders which are difficult to treat nowadays include primarily candidoses of the oral and vaginal mucosa.
Candidoses are defined as infections usually caused by Candida albicans, but also by a large number of other Candida species which grow opportunistically (C. krusei, C. tropicalis, Candida glabrata and many others). The yeast-like fungi which are often present anyway in the oral cavity, the gastrointestinal tract and the vagina grow under particular conditions and assume parasitic/pathogenic characteristics. Yeast-like fungi are able in some circumstances to colonize the skin and its appendages, all mucosae near the skin and several internal organs (esophagus, lung etc.) and, in this event, induce a remarkably wide range of disorders.
The occurrence of a candidosis may be favored in particular by pregnancy, metabolic disorders, infectious diseases, tumors and immunodeficiencies.
Locally favoring factors are regarded as being mechanical irritation (for example dentures), occlusion, moisture and moist heat.
The occurrence of extensive oral candidosis is nowadays regarded in most countries as one of the principal clinical signs of impaired functioning of the immune system. Persistent oral candidoses indicate in many HIV patients the transition to immunodecompensation. In advanced immunodeficiency there are also erosive, and sometimes ulcerative, inflammations involving the gingiva, and candidal balanitis, candidal vulvitis and Candida-related anal eczema are not uncommon. Intestinal infections and candidal sepsis are likewise observed.
In immunocompetent patients, nystatin is regarded as the agent of choice for local treatment of Candida infections, but clinical experience shows that nystatin therapy on its own is often insufficient in HIV-infected immunodeficient patients. In these cases, systemic therapy with antimycotics of the azole type is widely used. Candida strains resistant to azoles were virtually unknown up to 1989. However, the treatment of vaginal candidoses has often proven difficult due to the occurrence of mixed infections with the protozoal strains Trichomonas vaginalis and Entamoeba histolytica.
However, since the use of fluconazole for preventing recurrence of oropharyngeal candidoses in HIV patients, the number of azole resistances which have become known has increased dramatically. Up to and including the 1 st half of 1995, 98 publications in the specialist literature reported resistance of Candida strains to azoles.
The documents EP 0 241 918 or US 4 797 409 describe the preparation of 1-hydroxy-2-pyridones and their use for controlling mainly infections by fungi and yeast, and pharmaceuticals containing these compounds.
It is therefore an object of the present invention to provide topical pharmaceutical formulations which are suitable for breaking through exsistent intrinsic and acquired resistances of Candida strains to azoles, while simultaneously having activity on the problem organisms Trichomonas vaginalis and Entamoeba histolytica.
It has now been found that compounds of the formula I are outstandingly suitable for the treatment of candidoses caused by yeast strains with intrinsic and acquired azole resistance. Said compounds are also distinguished by their activity, which is sufficient for therapeutic purposes, on the problem organisms Trichomonas vaginalis and Entamoeba o- CA 02239520 1998-06-03 E_ -3-histolytica which are often the cause of the development of mixed infections in cases of vaginal candidosis.
The invention relates to the use of the compound of the formula I
Ra Ri R3 (n.
I
OH
in which R', R2 and R3, which are identical or different, are hydrogen atom or alkyl with 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical with 6 to 9 carbon atoms or a radical of the formula II
i (~.
x-cHa Y
where X is S or O, Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine, Z is a single bond or the divalent radicals O, S, -CR2- (R = H or C~-C4-alkyl) or other divalent radicals with 2-10 carbon and, where appropriate, oxygen and/or sulfur atoms linked to form a chain, and - when the radicals contain 2 or more oxygen and/or sulfur atoms -the latter must be separated from one another by at least 2 carbon atoms, and where 2 adjacent carbon atoms can also be linked together by a double bond, and the free valencies of the carbon atoms are saturated by H and/or C~-C4 alkyl groups, Ar is an aromatic ring system which has up to two rings and can be substituted by up to three radicals from the group of fluorine, chlorine, bromine, methoxy, C~-C4-alkyl, trifluoromethyl and trifluoromethoxy, for the preparation of a pharmaceutical for the treatment of fungal r CA 02239520 1998-06-03 disorders caused by azole-resistant fungi.
The compounds according to the invention are furthermore suitable for the treatment of trichomoniasis, one of the commonest causes, which is spread around the world, of non-gonorrheal urethritis. The disorder is caused by the pathogen Trichomonas vaginalis which is one of the protozoa.
The carbon chain members in the "Z" radicals are preferably CH2 groups.
If the CH2 groups are substituted by C~-C4-alkyl groups, CH3 and C2H5 are preferred substituents.
Examples of "Z" radicals are:
-O-, -S-, -CH2-, -(CH2)m (m=2-10), -C(CH3)2-, -CH20-, -OCH2-, -CH2S-, -S CH2-, -S CH (CZHS)-, -CH=CH-CH20-, -O-CH2-CH=CH-CH20-, -O CH2-CH20-, -O CHZ-CH2CH20-, -S CH2 CH2 CH2 S-, - S CH2 CH2 CH2 CH2 O-, -S CH2 CH2 O CHZ CH2 O-, -S CH2 CH2 O CH2 CH2 O-CH2 CHZ S-, or -S-CH2-C (CH3)2-CH2-S-.
The radical "S" is a sulfur atom, and the radical "O" is an oxygen atom. The term "Ar" means phenyl and condensed systems such as naphthyl, tetrahydronaphthyl and indenyl, and isolated systems such as those derived from biphenyl, diphenylalkanes, Biphenyl ethers and Biphenyl thioethers.
Principal representatives of the class of compounds characterized by the formula I are:
6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hyd roxy-4.-methyl-2-pyridone;
6-[4-(2,4-dichlorophenoxy)phenoxymethyl]-1-hydroxy-4.-methyl-2-pyridone;
6-(4-biphenylyloxymethyl)-1-hydroxy-4.-methyl-2-pyridone;
6-(4-benzyl phenoxymethyl )-1-hydroxy-4.-methyl-2-pyridone;
6-[4-(2,4-dichlorobenzyloxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone;
6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone;
r CA 02239520 1998-06-03 6-[4-(2,4-dichlorobenzyl)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone;
6-[4-(cinnamyloxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone;
1-hyd roxy-4-methyl-6-[4-(4-trifluoromethylphenoxy)phenoxymethyl]-2-pyridone;
1-hydroxy-4.-methyl-6-cyclohexyl-2-pyridone or 1-hydroxy-4.-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone.
The abovementioned compounds of the formula I can be employed both in free form and in the form of salts, and use in free form is preferred.
The compounds of the formula I to be employed in the formulations can be prepared, for example, by processes disclosed in US 2 540 218 or US
4 797 409.
The term "azole-resistant fungi" means all species of fungi or yeasts which have become resistant to antimycotics, for example to antimycotics which contain azole residues, such as fluconazole.
Immunosuppressed patients are preferably treated such as diabetics, asthmatics, smokers, AIDS patients, patients before and after transplants, cancer patients, patients chronically treated with antibiotics, cytostatics or corticosteroids, patients with antimycotic-resistant fungi, in particular patients with fluconazole-resistant fungi or elderly people.
Suitable for the use of said compounds according to the invention are liquid, semisolid and solid pharmaceutical formulations, in particular solutions, cream, ointment and gel formulations, and pastilles and pessaries.
The active substance is incorporated into the formulations according to the invention in amounts which are normally between about 0.05 and about 5%, preferably between 0.1 and 1 %.
Topical treatment of candidoses caused by yeast strains with intrinsic and acquired azole resistance with the pharmaceuticals according to the invention is able to achieve an effective cure.
The compositions according to the invention can also be employed successfully for the treatment of vaginal candidoses with mixed infections by the protozoal strains Trichomonas vaginalis and Entamoeba histolytica.
Example 1 A formulation according to the invention has the following composition:
6-[4-(4-Chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-0.50 2(1 H)-pyridone Hydroxyethylcellulose 1.50 Polyethylene glycol 7 glyceryl cocoate 5.00 1,2-Propylene glycol 10.00 Isopropyl alcohol 20.00 Demineralized water 63.00 Example 2 A formulation according to the invention has the following composition:
6-[4-(4-Chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-1.00 2(1 H)-pyridone 2-Octyldodecanol 5.00 Liquid paraffin 5.00 Cetyl alcohol 5.00 Stearyl alcohol 5.00 Myristyl alcohol 5.00 Polyoxyethylene 20 sorbitan monostearate 3.00 Sorbitan monostearate 2.00 Demineralized water 69.00 Example 3 A formulation according to the invention has the following composition:
6-Cyclohexyl-1-hydroxyl-methyl-2(1 H)-pyridone 5 mg Polyethylene glycol 1500 1500 mg Polyethylene glycol 4000 1000 mg Polyethylene glycol 6000 165 mg Sodium bicarbonate 180 mg Tartaric acid 150 mg Example 4 A formulation according to the invention has the following composition:
6-[4-(4-Chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl- 10 mg 2(1 H~pyridone Tylose C 1000 P
30 mg Polyethylene glycol 6000 500 mg Mannitol 305 mg Sodium stearyl fumarate 5 mg Example 5 Test of efficacy Determination of the efficacy of 6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2(1 H~pyridone (Compound 1 ) on fluconazole-resistant strains of Candida aibicans Fluconazole-resistant strains of Candida albicans are isolated from patients who have been treated, for example, with fluconazole for more than one year. For this purpose, samples are taken from the patients' mouths and applied, undiluted or diluted 1:100, to an RPMI 1640 agar (Gibco/BRL, Life Technologies GmbH, D-76339 Eggenstein) which contains about 1.0 Ng/ml fluconazole. Resistant Candida albicans strains are isolated, further purified on agar and stored isolated in ,.. CA 02239520 1998-06-03 _- _$_ peptone/dextrose slant agar tubes.
The activity of Compound 1 and fluconazole is determined by the microtiter dilution technique in RPMI 1640 medium. The growth medium RPMI 1640 buffered with 0.165 M morpholinopropanesulfonic acid pH 7.0 is introduced into 96-well microtiter plates. Serial dilutions by a factor of 2 are prepared for Compound 1 and fluconazole to result in final concentrations of 256 to 0.002 Ng/ml of Compound 1 and fluconazole. The microtiter plates prepared in this way are incubated with the Candida strains to be tested.
For comparison purposes, the finro Candida albicans strains ATCC 90028 and 90029 which are not resistant to fluconazole are included in the test.
The initial cell count is 1-5 x 103 colony-forming units per ml of growth medium. The microtiter plates are incubated at 35°C for 48 hours. The minimum inhibitory concentration is determined by photometry at 510 nm.
Table 1 shows the results:
r - _ 9 Table 1 Minimum inhibito concentration MIC
ml Strain Fluconazole Com ound 1 Candida albicans ATCC 900280.5 1 Candida aibicans ATCC 900291 0,5 Candida albicans 94/3 32 2 Candida albicans 94/14 32 2 Candida albicans 94/57 > 256 1 Candida albicans 94/62 > 256 1 Candida albicans 94/90 > 256 1 Candida albicans 94/118 > 256 2 Candida albicans 94/134 > 256 1 Candida albicans 94/138 > 256 1 Candida aibicans 94:/222 > 256 1 Candida albicans 94/231 > 256 1 Candida albicans B6 1 1 Candida albicans B70 > 256 1 Candida aibicans B75 2 1 Candida krusei B1 32 0.5 Candida krusei B4 16 1 Candida labrata B12 4 0.5 Candida labrata B14 2 0.5 Candida labrata B18 8 0.5 Candida labrata B21 8 1 Candida labrata B35 8 1 Candida labrata B37 16 1 Candida labrata B38 16 1 Candida labrata B39 8 0.5 Candida labrata B40 16 1 Candida labrata B50 16 0.5 Candida labrata B51 32 0.5 Candida uillermondii B47 4 1 Table 1 shows that Compound 1 impedes the growth of Candida strains in a very narrow concentration range -irrespective of existent fluconazole resistance.
Example 6 In vitro activity of the Compound 1 on protozoa n = MIC /ml Trichomonas vaginalis 5 31.2~3~ , 125~2~
Entamoeba histolytica 4 31.2 , 62.5~3~
n= number of strains investigated;
the number given in parentheses corresponds to the number of tested strains with which the stated MIC was determined.
The mucosal disorders which are difficult to treat nowadays include primarily candidoses of the oral and vaginal mucosa.
Candidoses are defined as infections usually caused by Candida albicans, but also by a large number of other Candida species which grow opportunistically (C. krusei, C. tropicalis, Candida glabrata and many others). The yeast-like fungi which are often present anyway in the oral cavity, the gastrointestinal tract and the vagina grow under particular conditions and assume parasitic/pathogenic characteristics. Yeast-like fungi are able in some circumstances to colonize the skin and its appendages, all mucosae near the skin and several internal organs (esophagus, lung etc.) and, in this event, induce a remarkably wide range of disorders.
The occurrence of a candidosis may be favored in particular by pregnancy, metabolic disorders, infectious diseases, tumors and immunodeficiencies.
Locally favoring factors are regarded as being mechanical irritation (for example dentures), occlusion, moisture and moist heat.
The occurrence of extensive oral candidosis is nowadays regarded in most countries as one of the principal clinical signs of impaired functioning of the immune system. Persistent oral candidoses indicate in many HIV patients the transition to immunodecompensation. In advanced immunodeficiency there are also erosive, and sometimes ulcerative, inflammations involving the gingiva, and candidal balanitis, candidal vulvitis and Candida-related anal eczema are not uncommon. Intestinal infections and candidal sepsis are likewise observed.
In immunocompetent patients, nystatin is regarded as the agent of choice for local treatment of Candida infections, but clinical experience shows that nystatin therapy on its own is often insufficient in HIV-infected immunodeficient patients. In these cases, systemic therapy with antimycotics of the azole type is widely used. Candida strains resistant to azoles were virtually unknown up to 1989. However, the treatment of vaginal candidoses has often proven difficult due to the occurrence of mixed infections with the protozoal strains Trichomonas vaginalis and Entamoeba histolytica.
However, since the use of fluconazole for preventing recurrence of oropharyngeal candidoses in HIV patients, the number of azole resistances which have become known has increased dramatically. Up to and including the 1 st half of 1995, 98 publications in the specialist literature reported resistance of Candida strains to azoles.
The documents EP 0 241 918 or US 4 797 409 describe the preparation of 1-hydroxy-2-pyridones and their use for controlling mainly infections by fungi and yeast, and pharmaceuticals containing these compounds.
It is therefore an object of the present invention to provide topical pharmaceutical formulations which are suitable for breaking through exsistent intrinsic and acquired resistances of Candida strains to azoles, while simultaneously having activity on the problem organisms Trichomonas vaginalis and Entamoeba histolytica.
It has now been found that compounds of the formula I are outstandingly suitable for the treatment of candidoses caused by yeast strains with intrinsic and acquired azole resistance. Said compounds are also distinguished by their activity, which is sufficient for therapeutic purposes, on the problem organisms Trichomonas vaginalis and Entamoeba o- CA 02239520 1998-06-03 E_ -3-histolytica which are often the cause of the development of mixed infections in cases of vaginal candidosis.
The invention relates to the use of the compound of the formula I
Ra Ri R3 (n.
I
OH
in which R', R2 and R3, which are identical or different, are hydrogen atom or alkyl with 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical with 6 to 9 carbon atoms or a radical of the formula II
i (~.
x-cHa Y
where X is S or O, Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine, Z is a single bond or the divalent radicals O, S, -CR2- (R = H or C~-C4-alkyl) or other divalent radicals with 2-10 carbon and, where appropriate, oxygen and/or sulfur atoms linked to form a chain, and - when the radicals contain 2 or more oxygen and/or sulfur atoms -the latter must be separated from one another by at least 2 carbon atoms, and where 2 adjacent carbon atoms can also be linked together by a double bond, and the free valencies of the carbon atoms are saturated by H and/or C~-C4 alkyl groups, Ar is an aromatic ring system which has up to two rings and can be substituted by up to three radicals from the group of fluorine, chlorine, bromine, methoxy, C~-C4-alkyl, trifluoromethyl and trifluoromethoxy, for the preparation of a pharmaceutical for the treatment of fungal r CA 02239520 1998-06-03 disorders caused by azole-resistant fungi.
The compounds according to the invention are furthermore suitable for the treatment of trichomoniasis, one of the commonest causes, which is spread around the world, of non-gonorrheal urethritis. The disorder is caused by the pathogen Trichomonas vaginalis which is one of the protozoa.
The carbon chain members in the "Z" radicals are preferably CH2 groups.
If the CH2 groups are substituted by C~-C4-alkyl groups, CH3 and C2H5 are preferred substituents.
Examples of "Z" radicals are:
-O-, -S-, -CH2-, -(CH2)m (m=2-10), -C(CH3)2-, -CH20-, -OCH2-, -CH2S-, -S CH2-, -S CH (CZHS)-, -CH=CH-CH20-, -O-CH2-CH=CH-CH20-, -O CH2-CH20-, -O CHZ-CH2CH20-, -S CH2 CH2 CH2 S-, - S CH2 CH2 CH2 CH2 O-, -S CH2 CH2 O CHZ CH2 O-, -S CH2 CH2 O CH2 CH2 O-CH2 CHZ S-, or -S-CH2-C (CH3)2-CH2-S-.
The radical "S" is a sulfur atom, and the radical "O" is an oxygen atom. The term "Ar" means phenyl and condensed systems such as naphthyl, tetrahydronaphthyl and indenyl, and isolated systems such as those derived from biphenyl, diphenylalkanes, Biphenyl ethers and Biphenyl thioethers.
Principal representatives of the class of compounds characterized by the formula I are:
6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hyd roxy-4.-methyl-2-pyridone;
6-[4-(2,4-dichlorophenoxy)phenoxymethyl]-1-hydroxy-4.-methyl-2-pyridone;
6-(4-biphenylyloxymethyl)-1-hydroxy-4.-methyl-2-pyridone;
6-(4-benzyl phenoxymethyl )-1-hydroxy-4.-methyl-2-pyridone;
6-[4-(2,4-dichlorobenzyloxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone;
6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone;
r CA 02239520 1998-06-03 6-[4-(2,4-dichlorobenzyl)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone;
6-[4-(cinnamyloxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone;
1-hyd roxy-4-methyl-6-[4-(4-trifluoromethylphenoxy)phenoxymethyl]-2-pyridone;
1-hydroxy-4.-methyl-6-cyclohexyl-2-pyridone or 1-hydroxy-4.-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone.
The abovementioned compounds of the formula I can be employed both in free form and in the form of salts, and use in free form is preferred.
The compounds of the formula I to be employed in the formulations can be prepared, for example, by processes disclosed in US 2 540 218 or US
4 797 409.
The term "azole-resistant fungi" means all species of fungi or yeasts which have become resistant to antimycotics, for example to antimycotics which contain azole residues, such as fluconazole.
Immunosuppressed patients are preferably treated such as diabetics, asthmatics, smokers, AIDS patients, patients before and after transplants, cancer patients, patients chronically treated with antibiotics, cytostatics or corticosteroids, patients with antimycotic-resistant fungi, in particular patients with fluconazole-resistant fungi or elderly people.
Suitable for the use of said compounds according to the invention are liquid, semisolid and solid pharmaceutical formulations, in particular solutions, cream, ointment and gel formulations, and pastilles and pessaries.
The active substance is incorporated into the formulations according to the invention in amounts which are normally between about 0.05 and about 5%, preferably between 0.1 and 1 %.
Topical treatment of candidoses caused by yeast strains with intrinsic and acquired azole resistance with the pharmaceuticals according to the invention is able to achieve an effective cure.
The compositions according to the invention can also be employed successfully for the treatment of vaginal candidoses with mixed infections by the protozoal strains Trichomonas vaginalis and Entamoeba histolytica.
Example 1 A formulation according to the invention has the following composition:
6-[4-(4-Chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-0.50 2(1 H)-pyridone Hydroxyethylcellulose 1.50 Polyethylene glycol 7 glyceryl cocoate 5.00 1,2-Propylene glycol 10.00 Isopropyl alcohol 20.00 Demineralized water 63.00 Example 2 A formulation according to the invention has the following composition:
6-[4-(4-Chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-1.00 2(1 H)-pyridone 2-Octyldodecanol 5.00 Liquid paraffin 5.00 Cetyl alcohol 5.00 Stearyl alcohol 5.00 Myristyl alcohol 5.00 Polyoxyethylene 20 sorbitan monostearate 3.00 Sorbitan monostearate 2.00 Demineralized water 69.00 Example 3 A formulation according to the invention has the following composition:
6-Cyclohexyl-1-hydroxyl-methyl-2(1 H)-pyridone 5 mg Polyethylene glycol 1500 1500 mg Polyethylene glycol 4000 1000 mg Polyethylene glycol 6000 165 mg Sodium bicarbonate 180 mg Tartaric acid 150 mg Example 4 A formulation according to the invention has the following composition:
6-[4-(4-Chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl- 10 mg 2(1 H~pyridone Tylose C 1000 P
30 mg Polyethylene glycol 6000 500 mg Mannitol 305 mg Sodium stearyl fumarate 5 mg Example 5 Test of efficacy Determination of the efficacy of 6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2(1 H~pyridone (Compound 1 ) on fluconazole-resistant strains of Candida aibicans Fluconazole-resistant strains of Candida albicans are isolated from patients who have been treated, for example, with fluconazole for more than one year. For this purpose, samples are taken from the patients' mouths and applied, undiluted or diluted 1:100, to an RPMI 1640 agar (Gibco/BRL, Life Technologies GmbH, D-76339 Eggenstein) which contains about 1.0 Ng/ml fluconazole. Resistant Candida albicans strains are isolated, further purified on agar and stored isolated in ,.. CA 02239520 1998-06-03 _- _$_ peptone/dextrose slant agar tubes.
The activity of Compound 1 and fluconazole is determined by the microtiter dilution technique in RPMI 1640 medium. The growth medium RPMI 1640 buffered with 0.165 M morpholinopropanesulfonic acid pH 7.0 is introduced into 96-well microtiter plates. Serial dilutions by a factor of 2 are prepared for Compound 1 and fluconazole to result in final concentrations of 256 to 0.002 Ng/ml of Compound 1 and fluconazole. The microtiter plates prepared in this way are incubated with the Candida strains to be tested.
For comparison purposes, the finro Candida albicans strains ATCC 90028 and 90029 which are not resistant to fluconazole are included in the test.
The initial cell count is 1-5 x 103 colony-forming units per ml of growth medium. The microtiter plates are incubated at 35°C for 48 hours. The minimum inhibitory concentration is determined by photometry at 510 nm.
Table 1 shows the results:
r - _ 9 Table 1 Minimum inhibito concentration MIC
ml Strain Fluconazole Com ound 1 Candida albicans ATCC 900280.5 1 Candida aibicans ATCC 900291 0,5 Candida albicans 94/3 32 2 Candida albicans 94/14 32 2 Candida albicans 94/57 > 256 1 Candida albicans 94/62 > 256 1 Candida albicans 94/90 > 256 1 Candida albicans 94/118 > 256 2 Candida albicans 94/134 > 256 1 Candida albicans 94/138 > 256 1 Candida aibicans 94:/222 > 256 1 Candida albicans 94/231 > 256 1 Candida albicans B6 1 1 Candida albicans B70 > 256 1 Candida aibicans B75 2 1 Candida krusei B1 32 0.5 Candida krusei B4 16 1 Candida labrata B12 4 0.5 Candida labrata B14 2 0.5 Candida labrata B18 8 0.5 Candida labrata B21 8 1 Candida labrata B35 8 1 Candida labrata B37 16 1 Candida labrata B38 16 1 Candida labrata B39 8 0.5 Candida labrata B40 16 1 Candida labrata B50 16 0.5 Candida labrata B51 32 0.5 Candida uillermondii B47 4 1 Table 1 shows that Compound 1 impedes the growth of Candida strains in a very narrow concentration range -irrespective of existent fluconazole resistance.
Example 6 In vitro activity of the Compound 1 on protozoa n = MIC /ml Trichomonas vaginalis 5 31.2~3~ , 125~2~
Entamoeba histolytica 4 31.2 , 62.5~3~
n= number of strains investigated;
the number given in parentheses corresponds to the number of tested strains with which the stated MIC was determined.
Claims (8)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. The use of a compound of the formula I
where R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
where X is S or O;
Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;
Z is a single bond or a bivalent radical comprising:
(1) O, or (2) S, or (3) ~CR2-, where R is H or (C1-C4)-alkyl, or (4) from 2 to 10 carbon atoms linked in the form of a chain, which optionally further comprises one or more of the following:
(i) a carbon-carbon double bond, or (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and in any of the foregoing bivalent radicals, free valences of the carbon atoms of said bivalent radical are saturated by H, (C1-C4)-alkyl, or a mixture thereof;
and Ar is an aromatic ring system having one or two rings which can be substituted by one, two or three radicals, which may be identical or different, which are halogen, methoxy, (C1-C4)-alkyl, trifluoromethyl or trifluoromethoxy, a physiologically tolerated salt of the compound of the formula I or a mixture thereof, for the preparation of a pharmaceutical for the topical treatment of fungal disorders caused by fluconazole-resistant fungi or fluconazole resistant yeast or a combination thereof.
where R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
where X is S or O;
Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;
Z is a single bond or a bivalent radical comprising:
(1) O, or (2) S, or (3) ~CR2-, where R is H or (C1-C4)-alkyl, or (4) from 2 to 10 carbon atoms linked in the form of a chain, which optionally further comprises one or more of the following:
(i) a carbon-carbon double bond, or (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and in any of the foregoing bivalent radicals, free valences of the carbon atoms of said bivalent radical are saturated by H, (C1-C4)-alkyl, or a mixture thereof;
and Ar is an aromatic ring system having one or two rings which can be substituted by one, two or three radicals, which may be identical or different, which are halogen, methoxy, (C1-C4)-alkyl, trifluoromethyl or trifluoromethoxy, a physiologically tolerated salt of the compound of the formula I or a mixture thereof, for the preparation of a pharmaceutical for the topical treatment of fungal disorders caused by fluconazole-resistant fungi or fluconazole resistant yeast or a combination thereof.
2. The use as claimed in claim 1, wherein a compound of the formula I in which Y is chlorine and/or bromine is employed.
3. The use as claimed in claim 1, wherein a compound of the formula I in which Ar is a phenyl ring, and R1 and R3 are a hydrogen atom, and R2 is methyl, is employed.
4. The use as claimed in claim 1, wherein a compound of the formula I in which Ar is a bicyclic system derived from biphenyl, diphenylalkane or diphenyl ether is employed.
5. The use as claimed in any one of claims 1 to 4, wherein a compound of the formula I in which Z is a single bond or Z is oxygen is employed.
6. The use as claimed in claim 1, wherein 6-[4-(4-chlorophenoxy) phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone is employed.
7. The use as claimed in any one of claims 1 to 6 for the preparation of a pharmaceutical for the treatment of fungal disorders caused by yeast which has an intrinsic and/or acquired fluconazole resistance.
8. The use as claimed in any one of claims 1 to 7 for the treatment of vaginal candidoses.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1995143831 DE19543831C2 (en) | 1995-11-26 | 1995-11-26 | Turnbuckle for jewelry items |
| DE19545139.2 | 1995-12-04 | ||
| DE19545139A DE19545139C1 (en) | 1995-12-04 | 1995-12-04 | Use of 1-hydroxy-pyridone cpds. to control yeast and fungi |
| DE19543831.4 | 1996-10-30 | ||
| PCT/EP1996/005132 WO1997020560A1 (en) | 1995-12-04 | 1996-11-21 | Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2239520A1 CA2239520A1 (en) | 1997-06-12 |
| CA2239520C true CA2239520C (en) | 2006-01-17 |
Family
ID=26020639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002239520A Expired - Fee Related CA2239520C (en) | 1995-11-26 | 1996-11-21 | Use of 1-hydroxy-2-pyridones for treating mucosal disorders which are difficult to treat |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2239520C (en) |
-
1996
- 1996-11-21 CA CA002239520A patent/CA2239520C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2239520A1 (en) | 1997-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7868162B2 (en) | Antimicrobial and antiviral compounds and methods for their use | |
| DK2311466T3 (en) | Antimicrobial compositions and methods for their application | |
| US20080057136A1 (en) | Disinfecting Composition and Methods of Making and Using Same | |
| US6455551B1 (en) | Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat | |
| CA2018641A1 (en) | N-substituted lauramides, their preparation and compositions in which they are present | |
| TW202206066A (en) | Pharmaceutical composition for preventing or treating tinea and use thereof | |
| EP0288352A1 (en) | Aromatic derivatives, their preparation and their use as antimicrobics | |
| HUT61660A (en) | Process for producing pharmaceutical and agrochemical copositions containing beta-hydroxy-ethyl-amine derivatives as active components | |
| CA2239520C (en) | Use of 1-hydroxy-2-pyridones for treating mucosal disorders which are difficult to treat | |
| JP2003503347A (en) | Treatment of fungal infections using inhibitors of NAD synthetase enzyme | |
| KR100460164B1 (en) | Pharmaceutical composition for the treatment of intractable mucosal diseases comprising 1-hydroxy-2-pyridone | |
| EP0105448B1 (en) | The use of undecylenic acid for the manufacture of a composition for the treatment of herpes labialis | |
| EP3268008B1 (en) | Compounds that are analogs of squalamine, used as antibacterial agents | |
| EP1803453A1 (en) | Carbamate antibiotics | |
| CA1174169A (en) | Orally active tolciclate and tolnaftate | |
| JP4106454B2 (en) | Compositions for treating acne containing phytandiolamine (Compositions for treating acne competing phytiodiolamine) | |
| FR2470110A1 (en) | DECRAPENYLAMINE DERIVATIVES, THEIR ACID ADDITION SALTS AND PHARMACEUTICAL COMPOSITION COMPRISING THESE PRODUCTS | |
| HU192567B (en) | Process for preparing benzamidine derivatives | |
| US5807898A (en) | Antimalarial agents | |
| FR2579979A1 (en) | ||
| GB1588095A (en) | Composition for the treatment of scabies | |
| JPS60500372A (en) | New drug based on halogenobenzophenone-oxime derivatives | |
| JPS63238060A (en) | Quinoline derivative | |
| AU2013276985B2 (en) | Antimicrobial and antiviral compounds and methods for their use | |
| JP3805900B2 (en) | Antifungal agent and composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20151123 |